Drug Profile


Alternative Names: Famitinib maleate; SHR 1020

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase II Gastrointestinal stromal tumours; Neuroendocrine tumours; Renal cell carcinoma
  • No development reported Breast cancer; Nasopharyngeal cancer

Most Recent Events

  • 06 May 2016 Jiangsu Hengrui Medicine plans a phase III trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic disease; Second-line therapy or greater) in China (NCT02766140)
  • 01 May 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent, Combination therapy) in China (PO)
  • 31 Jan 2016 Jiangsu Hengrui Medicine completes enrolment in a phase II trial for Gastrointestinal stromal tumours (Inoperable/Unresectable, Late-stage disease) in China (NCT02336724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top